top of page

PATENTS &

DRUG CANDIDATES

Anti-Inflamation

May 2024

Curadev announces the publication of its PCT application covering heterocyclic inhibitors of Cdc-like Kinases 

Read more...

February 2023

Curadev announces the publication of its PCT application covering small molecule STING antagonists

Read more...

February 2023

Curadev announces the publication of its PCT application covering small molecule urea derivatives as STING antagonists

Read more...

Cancer Metabolism

January 2021

Curadev announces the publication of its PCT application covering small molecule ACSS2 inhibitors

Immune Oncology & Host Immunity

May 2024

Curadev announces the publication of its PCT application covering pyridone and pyrimidinone inhibitors of hematopoetic progenitor kinase 1

Read more...

December 2019

Curadev announces the publication of its  PCT applications claiming ADCs and other conjugates for its small molecule STING activator program

December 2019

Curadev announces the publication of its PCT application covering a unique small molecule STING activator chemotype

December 2018

Curadev announces the publication of three PCT applications covering distinct small molecule STING activator chemotypes

June 2018

Curadev files three PCT applications covering distinct small molecule chemotypes in its STING activator program CDV015

May 2018

Certificates of grant received from major international markets for the Curadev small molecule IDO and TDO dual inhibitor patent

February 2016

Curadev announces the publication of its third PCT application covering small molecule inhibitors of the kynurenine pathway

November 2014

Curadev announces the publication of its  second PCT application covering small molecule inhibitors of the kynurenine pathway

September 2014

Curadev announces the publication of its  first PCT application covering small molecule inhibitors of the kynurenine pathway

Drug Delivery and Diagnostics

December 2021

Curadev announces the publication of PCT application titled Rapid Method for Genotyping STING variants in human individuals

Read more...

June 2021

European Patent Office upholds Curadev's cyclodextrin patent for new composition of matter

Read more...

April 2018

Certificates  of grant received from major international markets for the Curadev cyclodextrin derivative patent

January 2015

Curadev Pharma files a PCT application in its sponsored program with the University of Greenwich, UK

Patents & Drug Candidates
Recognition

RECOGNITION

August 2021

Curadev is in Industry Outlook Magazine's list of the top 10 Biotechnology companies in India

Read more...

 

April 2019

Curadev's abstract entitled "CRD5500: LB061 was selected as “The most interesting one for the session on targeted immunotherapeutics presenting the landscape of research in Antibody Drug Conjugate (ADC) and Small Molecule Immunotherapy (SMI)” at AACR meeting held in Atlanta, Georgia

January 2018

Success story of Curadev was featured on IIT, Kanpur website

Read more...

Sept 2016

Curadev was profiled by The Economic Times in an article titled -  Global healthcare companies seek to bet on Indian startups for fresh start

Read more...

April 2016

Curadev received funding approval from the Department of Biotechnology, India, under its SBIRI scheme

March 2016

20 companies chosen as India's Emerging 20 by London Partners. Leaders of these companies were invited to open the London Stock Exchange

Read more...

December 2011

Curadev’s In-House R&D unit received official recognition by the Department of Scientific and Industrial Research (DSIR)

September 2011

Curadev received permission to operate its vivarium from the CPSCEA, Ministry of Environment and Forestry, Government of India

September 2011

Curadev received permission to use radioactivity in its dedicated R&D lab from the Atomic Energy Regulatory Board, Government of India

March 2011

Curadev receives World Bank funding under the Sponsored Research and Development (SPREAD) Programme administered by the Technology Finance Group of ICICI Bank, headed by Mr. Jaisingh Dhummal. The objective of this program is to stimulate technology development through private investment in R&D and strengthen industry & technology institution (TI) collaboration. The Curadev project was selected based on its innovative content, likely impact and commercial value

Licensing & Partnerships

OUTLICENSING &

STRATEGIC PARTNERSHIPS

April 2020

Curadev and Karyopharm, USA sign a drug discovery collaboration agreement under which Curadev will select a target for co-development until Phase 1 clinical trials before handing the drug candidate over to Karyopharm for further development

Read more...

March 2020

Curadev and Bayer, Germany, sign a research collaboration and license agreement to develop novel STING antagonists

Read more...

September 2019

Curadev receives first milestone payment from the out-licensing of its novel small molecule STING agonist to Takeda Pharmaceuticals

May 2019

Curadev announces licensing of its patents covering its novel small molecule STING agonists to Takeda Pharmaceuticals

Read more...

April 2015

Curadev announces research collaboration and licensing agreement to develop cancer immunotherapeutic with Roche  

Read more...

May 2013

Curadev partners its dual kinase inhibitor program with Medivation, Inc, USA

September 2012

Curadev receives first milestone payment in its immune oncology small molecule collaboration with Endo Pharma

October 2011

Curadev signs extensive research collaboration deal with Medivation, Inc, USA

April 2011

Curadev announces research collaboration and licensing agreement to develop cancer immunotherapeutic with Endo Pharma

ACADEMIC 

COLLABORATIONS

October 2020

Curadev initiates a collaboration with clinicians at Christian Medical College, Vellore to study kynurenine levels in dengue patients

Read more...

July 2020

Curadev initiates a collaboration with Dana Farber Cancer Institute to identify drug combinations and patient populations that would benefit from Curadev’s advanced pre-clinical immune-oncology drug candidates

Read More...

October 2017

UT Southwestern Medical Center in Dallas, USA, and Curadev Pharma, India, announce a translational research partnership to identify small molecule drugs for the treatment of specific cancers 

Read more...

October 2016

Curadev initiates a collaboration with INSERM’s Professor Pierre Gressens, a leading clinician neuroscientist to identify drug targets underlying CNS pathologies

Read more...

July 2011

Curadev signs research collaboration with the University of Greenwich. to create novel process improvements for a range of commercially valuable pharmaceuticals

Read more...

March 2011

Curadev signs an agreement with the SIDBI incubation Center at the Indian Institute of Technology, Kanpur, (IITK)

Read more...

Academic Collaboration

COMPANY &

PEOPLE

February 2024
Curadev Announces First Treatment Cycle Completion for the First Patient Dosed in a Phase 1 a/b Clinical Trial of its Allosteric STING Agonist CRD3874-SI in Patients with Advanced Cancer at Memorial Sloan Kettering Cancer Center in New York

Read more...

February 2024
Curadev's Differentiated Next Generation STING Agonist CRD3874-SI
Read more...

April 2023

Curadev Pharma's Corporate Social Responsibility (CSR) projects- an update
Read more...

March 2023
Initiatives undertaken by Curadev under its Recognising Excellence campaign
Read more...

January 2023

Curadev Pharma announces the formation of its Clinical Advisory Group (CAG)
Read more...

December 2022
Curadev Pharma Receives FDA 'Study May Proceed' Letter for its Investigational New Drug Application of CRD3874, an IV-Administered STING Agonist for the treatment of advanced/metastatic solid cancers
Read more...


November 2022
Curadev Pharma joins NBEC to boost Indian Biotech Start ups: Sponsors Cash Prize for the second year in a row
Read more...

SEPTEMBER 2022

Curadev has sponsored a two-day seminar "Modern Trends in Technology" organized by Department of Microbiology, St. Xavier's College, Kolkata
View image...

AUGUST 2022
Curadev has sponsored the In-House Chemistry symposium organized by Shiv Nadar University from 26th-27th August 2022

View image...

January 2022
Curadev announces the formation of its Clinical Advisory Group (CAG) to provide guidance in the design and execution on oncology clinical trials

September 2021
A tree plantation drive was carried out by the Curadev Team in Noida Authority Park. The aim of the event was to create awareness and protect the environment by motivating everyone to take care of the surroundings we are part of
View image...

August 2021
As part of its focus on recognizing and promoting excellence, Curadev has sponsored the Gold Medal awarded to the top  ranked Masters student of the Pharmacology & Toxicology department at the National Institute of Pharmaceutical Research and Training at Guwahati (NIPER, Guwahati)

August 2021
Curadev has partnered with C-CAMP (Centre for Cellular and Molecular Platforms) for National Bio Entrepreneurship Competition (NBEC), 2021
Read more...

November  2020
Diwali Donation Camp: As part of Personal Social Responsibility (PSR), team Curadev has donated clothing, footwear and stationery at large to NGO "Goonj"

January 2020
Curadev celebrates its 10th anniversary

May 2017
Professor Satyajit Rath has joined Curadev’s Scientific Advisory Board
Read more...

October 2016
Dr. Shyamala Mani has joined Curadev as Director R&D
Read more...

April 2016
Dr. David Pryde has joined Curadev as Director R&D bringing his extensive experience in drug discovery to the team
Read more...

January 2016
Curadev announces the incorporation of Curadev UK

June 2015
Dr. Sourav Basu has joined Curadev as Vice President (R&D)
Read more...
 
October 2012
Curadev Pharma is 1000 days young

Company & People
Conferences & Meetings

CONFERENCES &

MEETINGS

2024

Senior Representatives of Curadev attended:

 

2023

Senior Representatives of Curadev attended:

 

2022

Senior Representatives of Curadev attended:

2021

Mr. Manish Tandon was invited as a Guest Speaker in the virtual event celebrating World Intellectual Property Week co-organized by FICPI, INTA, AIPPI, APAA, and Lex Witness

2020

Senior Representatives of Curadev attended:

 

Senior Representatives of Curadev were invited as speakers:

  • Dr. Arjun Surya gave a talk at the Annual Biological Sciences and Bioengineering (BSBE) Symposium in IIT, Kanpur

  • Dr. Arjun Surya was invited as a Guest Speaker in the "International Conference on Drug Discovery" organized at BITS Pilani, Hyderabad from 29th February to 2nd March

2019

Senior Representatives of Curadev attended:

 

2018

Senior Representatives of Curadev attended:

2017

Senior Representatives of Curadev attended:

  • The Society for Immunotherapy of Cancer (SITC), Washington, D.C., USA

  • The Asia Congress of the European Society for Medical Oncology (ESMO), Singapore

  • The Annual BIO meeting, San Diego, USA

  • The Tumor Immunology and Immunotherapy meeting of the in Boston, USA

  • The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA

  • The Annual meeting of the American Society for Cancer Research (AACR), Washington,DC, USA. Curadev presented poster titled: Novel small-molecule human STING agonists generate robust Type I interferon responses in tumors

  • The Annual J.P. Morgan Health Care Conference, San Francisco, USA

  • The Keystone Symposium on Tumor Metabolism and Hypoxia, Whistler, Canada

2016

Senior Representatives of Curadev attended:

  • The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA

  • The Annual meeting of the American Society for Cancer Research (AACR), New Orleans, USA where Curadev and Roche scientists presented a jointly authored poster titled: RG70099: A novel, highly potent dual TDO/IDO1 inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment.

  • The Mastering Medicinal Chemistry Conference, Boston, USA

  • The Society for Immunotherapy of Cancer (SITC), Washington, D.C., USA

  • The Asia Congress of the European Society for Medical Oncology (ESMO), Singapore

  • The Annual BIO meeting, San Francisco, USA

2015

Senior Representatives of Curadev attended:

2014

Senior Representatives of Curadev attended:

  • The Tumor Immunology and Immunotherapy meeting of the American Society for Cancer Research (AACR) in Orlando, USA where Curadev presented a poster titled: a small molecule dual inhibitor of TDO and IDO

  • The Annual BIO meeting, San Diego, USA

  • The Annual BIO Asia International Conference meeting, Tokyo, Japan

  • The Immunotherapy of Cancer (ITOC) conference in Munich, Germany

2013

Senior Representatives of Curadev attended:

  •  The Annual BIO meeting, Chicago, USA

bottom of page